Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against Neisseria meningitidis groups B and C

Journal of Immunology

Volumn 182, Issue 10, 2009, Pages 6610-6617

  Moe, Gregory R ^a   Bhandari, Tamara S ^a,b   Flitter, Becca A ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BIOVERIS; DE N ACETYL SIALIC ACID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEURAMINIC ACID; POLYSIALIC ACID; SIALIC ACID DERIVATIVE; SIALIDASE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; DRUG ACETYLATION; DRUG CONJUGATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IMMUNOGENICITY; MENINGOCOCCEMIA; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BLOTTING, WESTERN; COMPLEMENT ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; N-ACETYLNEURAMINIC ACID; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; RATS; SIALIC ACIDS; VACCINES, CONJUGATE;

EID: 77952365730     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803677     Document Type: Article

References (35)

1. Jodar, L., I. Feavers, D. Salisbury, and D. M. Granoff. 2002. Development of vaccines against meningococcal disease. Lancet 359: 1499-1508. (Pubitemid 34457772)
2. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, L. Lefkowitz, M. L. Cartter, R. Danila, P. Cieslak, K. A. Shutt, T. Popovic, A. Schuchat, et al. 1999. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180: 1894-1901.
3. Finne, J., M. Leinonen, and P. H. Makela. 1983. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 2: 355-357. (Pubitemid 13028927)
4. Jennings, H. J. 1989. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development. Contri.b Microbiol. Immunol. 10: 151-165.
5. Finne, J., D. Bitter-Suermann, C. Goridis, and U. Finne. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol. 138: 4402-4407.
6. Granoff, D. M., A. Bartoloni, S. Ricci, E. Gallo, D. Rosa, N. Ravenscroft, V. Guarnieri, R. C. Seid, A. Shan, W. R. Usinger, et al. 1998. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 160: 5028-5036.
7. Ashton, F. E., J. A. Ryan, F. Michon, and H. J. Jennings. 1989. Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb. Pathog. 6: 455-458.
8. Pon, R. A., M. Lussier, Q. L. Yang, and H. J. Jennings. 1997. N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J. Exp. Med. 185: 1929-1938.
9. Moe, G. R., A. Dave, and D. M. Granoff. 2005. Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect. Immun. 73: 2123-2128.
10. Moe, G. R., and D. M. Granoff. 2001. Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int. Rev. Immunol. 20: 201-221.
11. Moe, G. R., S. Tan, and D. M. Granoff. 1999. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. Microbiol. 26: 209-226.
12. Cobb, B. A., and D. L. Kasper. 2005. Zwitterionic capsular polysaccharides: the new MHCII-dependent antigens. Cell. Microbiol. 7: 1398-1403.
13. Cobb, B. A., and D. L. Kasper. 2008. Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. Glycobiology 18: 707-718.
14. Cobb, B. A., Q. Wang, A. O. Tzianabos, and D. L. Kasper. 2004. Polysaccharide processing and presentation by the MHCII pathway. Cell 117: 677-687.
15. Berry, J. D., D. J. Boese, D. K. Law, W. D. Zollinger, and R. S. Tsang. 2005. Molecular analysis of monoclonal antibodies to group variant capsular polysaccharide of Neisseria meningitidis: recurrent heavy chains and alternative light chain partners. Mol. Immunol. 42: 335-344.
16. Moe, G. R., A. Dave, and D. M. Granoff. 2006. Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Mol. Immunol. 43: 1424-1431.
17. Welsch, J. A., G. R. Moe, R. Rossi, J. Adu-Bobie, R. Rappuoli, and D. M. Granoff. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188: 1730-1740.
18. Uchida, Y., Y. Tsukada, and T. Sugimori. 1979. Enzymatic properties of neuraminidases from Arthrobacter ureafaciens. J. Biochem. 86: 1573-1585. (Pubitemid 10217049)
19. Mandrell, R. E., and W. D. Zollinger. 1982. Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants. J. Immunol. 129: 2172-2178.
20. Coquillat, D., J. Bruge, B. Danve, M. Latour, C. Hurpin, D. Schulz, P. Durbec, and G. Rougon. 2001. Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate. Infect. Immun. 69: 7130-7139.
21. Manzi, A. E., H. H. Higa, S. Diaz, and A. Varki. 1994. Intramolecular self-cleavage of polysialic acid. J. Biol. Chem. 269: 23617-23624.
22. Frosch, M., I. Gorgen, G. J. Boulnois, K. N. Timmis, and D. Bitter-Suermann. 1985. NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc. Natl. Acad. Sci. USA 82: 1194-1198.
23. Gallorini, S., F. Berti, P. Parente, R. Baronio, S. Aprea, U. D'Oro, M. Pizza, J. L. Telford, and A. Wack. 2007. Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J. Immunol. 179: 8208-8215.
24. Flitter, B. A., and G. R. Moe. 2008. Protective anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies are reactive with noncapsular antigens expressed by group A, B, C, and W135 strains. In 16th International Pathogenic Neisseria Conference 2008. Congress Care, Rotterdam, The Netherlands.
25. Moe, G. R., and D. M. Granoff. 2001. Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int. Rev. Immunol. 20: 201-220. (Pubitemid 33119076)
26. Welsch, J. A., and D. Granoff. 2007. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin. Vaccine Immunol. 14: 1596-1602.
27. Ross, S. C., P. J. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155: 1266-1275.
28. Delvig, A., S. Jahn, B. Kusecek, J. E. Heckels, E. Rosenqvist, E. A. Hoiby, T. E. Michaelsen, and M. Achtman. 1994. A comparison of human and murine monoclonal IgGs specific for the P1.7 PorA protein of Neisseria meningitidis. Mol. Immunol. 31: 1257-1267.
29. Raff, H. V., D. Devereux, W. Shuford, D. Abbott-Brown, and G. Maloney. 1988. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections. J. Infect. Dis. 157: 118-126.
30. Toropainen, M., L. Saarinen, E. Wedege, K. Bolstad, T. E. Michaelsen, A. Aase, and H. Kayhty. 2005. Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis. Infect. Immun. 73: 4694-4703.
31. Hanai, N., T. Dohi, G. A. Nores, and S. Hakomori. 1988. A novel ganglioside, de-N-acetyl-GM3 (II3NeuNH2LacCer), acting as a strong promoter for epidermal growth factor receptor kinase and as a stimulator for cell growth. J. Biol. Chem. 263: 6296-6301.
32. Chammas, R., J. L. Sonnenburg, N. E. Watson, T. Tai, M. G. Farquhar, N. M. Varki, and A. Varki. 1999. de-N-acetyl-gangliosides in humans: unusual subcellular distribution of a novel tumor antigen. Cancer Res. 59: 1337-1346.
33. Sjoberg, E. R., R. Chammas, H. Ozawa, I. Kawashima, K. H. Khoo, H. R. Morris, A. Dell, T. Tai, and A. Varki. 1995. Expression of de-N-acetyl- gangliosides in human melanoma cells is induced by genistein or nocodazole. J. Biol. Chem. 270: 2921-2930.
34. Manzi, A. E., E. R. Sjoberg, S. Diaz, and A. Varki. 1990. Biosynthesis and turnover of O-acetyl and N-acetyl groups in the gangliosides of human melanoma cells. J. Biol. Chem. 265: 13091-13103.
35. Popa, I., A. Pons, C. Mariller, T. Tai, J. P. Zanetta, L. Thomas, and J. Portoukalian. 2007. Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors. Glycobiology 17: 367-373. (Pubitemid 46432008)